

**EARLY WARNING REPORT
PURSUANT TO NATIONAL INSTRUMENT 62-103**

Section 102 of the *Securities Act* (Ontario)

1. Name and address of the offeror:

Invidx Corp. (the “Offeror”)
6 Trout Lily Ave
Markham, ON L3S 4C1

2. Name of reporting issuer with respect to which this report is filed:

Monarch Energy Limited (the “Company”)

3. Designation and number or principal amount of securities and the offeror’s securityholding percentage in the class of securities of which the offeror acquired ownership or control in the transaction or occurrence giving rise to the obligation to file the report, and whether it was ownership or control that was acquired in those circumstance:

On June 30, 2014, the Offeror acquired 15,000,100 common shares in the capital of the Company (“**Common Shares**”) from the Company, representing approximately 50.39% of the outstanding Common Shares of the Company in connection with the acquisition of ChromedX Ltd. (“**ChroMedX**”) by the Company (the “**Acquisition**”).

4. Designation and number or principal amount of securities and the offeror’s securityholding percentage in the class of securities immediately after the transaction or occurrence giving rise to obligation to file the report:

Following the Acquisition indicated in paragraph 3, the Offeror, directly holds an aggregate of 15,000,100 Common Shares, representing approximately 50.39% of the outstanding Common Shares (based on 29,767,693 issued and outstanding Common Shares as at the date hereof). The Offeror does not own any convertible securities of the Company.

5. Designation and number or principal amount of securities and the percentage of outstanding securities of the class of securities referred to in paragraph 4 over which:

- (i) **the offeror, either alone or together with any joint actors, has ownership and control;**

The Offeror directly owns the securities referred to in paragraph 4.

- (ii) **the offeror, either alone or together with any joint actors, has ownership but control is held by other persons or companies other than the offeror or any joint actor; and**

Not applicable.

- (iii) **the offeror, either alone or together with any joint actors, has exclusive or shared control but does not have ownership.**

Not applicable.

6. **Name of the market in which the transaction or occurrence that gave rise to the report took place:**

Not applicable. The Common Shares were issued to the Offeror by the Company from its treasury in connection with a Transaction – see Paragraph 9.

7. **The value, in Canadian dollars, of any consideration offered per security if the offeror acquired ownership of a security in the transaction or occurrence giving rise to the obligation to file a report.**

The Company issued to the Offeror 15,000,100 Common Shares at a deemed price of \$0.10 per share. The Offeror, in consideration for issuance of the 15,000,100 Common Shares received from the Company, transferred 15,000,100 common shares in the capital of ChroMedX to the Company in connection with the Acquisition – see paragraph 9.

8. **Purpose of the offeror and any joint actors in effecting the transaction or occurrence that gave rise to the report, including any future intention to acquire ownership of, or control over, additional securities of the reporting issuer:**

The Offeror has acquired the above-noted securities of the Company for investment purposes and the Offeror may, depending on market and other conditions, increase or decrease its beneficial ownership, control or direction over the common shares or other securities of the Company, through market transactions, private agreements, treasury issuances, exercise of convertible securities or otherwise. See also paragraph 9.

9. **General nature and the material terms of any agreement, other than lending arrangements, with respect to securities of the reporting issuer entered into by the offeror, or any joint actor, and the issuer of the securities or any other entity in connection with the transaction or occurrence giving rise to the report, including agreements with respect to the acquisition, holding, disposition or voting of any of the securities:**

ChroMedX entered into a Share Exchange Agreement dated December 20, 2013 (as amended on January 22, 2014, April 16, 2014 and May 6, 2014) (the “**Share Exchange Agreement**”), with the Company for the acquisition by the Company of all of the issued and outstanding common shares of ChroMedX (the “**ChroMedX Shares**”) in exchange for Common Shares of the Company.

In accordance with the terms of the Share Exchange Agreement, the shareholders of ChroMedX have transferred all of the ChroMedX Shares to the Company in exchange for an aggregate 24,625,100 Common Shares of the Company at a deemed price of \$0.10 per Common Share and share purchase warrants for the purchase of up to an aggregate 5,925,000 Common Shares of the Company at exercise prices ranging from \$0.15 to

\$0.25 per Common Share until expiry dates ranging from 12 months to 24 months from the date of listing on a stock exchange.

10. Names of any joint actors in connection with the disclosure required by this report:

Not applicable.

11. In the case of a transaction or occurrence that did not take place on a stock exchange or other market that represents a published market for the securities, including an issuance from treasury, the nature and value of the consideration paid by the offeror.

The Common Shares were issued to the Offeror by the Company from its treasury in connection with a Transaction – see Paragraph 9.

12. Where applicable, a description of any change in any material fact set out in a previous report filed under the early warning requirements of applicable Canadian securities legislation.

Not applicable.

13. Where applicable, a description of the exemption from securities legislation being relied on by the offeror and the facts supporting the reliance.

Not applicable.

DATED this 7th day of July, 2014.

INVIDIX CORP.

Per: “James Samsoundar” (signed)

Name: James Samsoundar

Title: President